ANDA 206682, held by Fresenius. Nafcillin Sodium.
As of Nov 16, 2026, ANDA 206682 (Nafcillin Sodium), held by Fresenius, was first approved by FDA on Dec 10, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 10, 2019 | Original application | Approved | None posted |
| Nafcillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Discontinued |
| Nafcillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters